MARKET

APVO

APVO

Aptevo Therapeutics Inc
NASDAQ
2.456
+0.076
+3.20%
Opening 10:45 03/14 EDT
OPEN
2.410
PREV CLOSE
2.380
HIGH
2.480
LOW
2.410
VOLUME
2.40K
TURNOVER
--
52 WEEK HIGH
209.38
52 WEEK LOW
2.354
MARKET CAP
3.58M
P/E (TTM)
-0.0008
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at APVO last week (0303-0307)?
Weekly Report · 4d ago
Weekly Report: what happened at APVO last week (0224-0228)?
Weekly Report · 03/03 10:18
Weekly Report: what happened at APVO last week (0217-0221)?
Weekly Report · 02/24 10:18
Roth MKM Sticks to Its Buy Rating for Aptevo Therapeutics (APVO)
TipRanks · 02/18 13:45
Weekly Report: what happened at APVO last week (0210-0214)?
Weekly Report · 02/17 10:16
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Barchart · 02/15 12:59
APTEVO THERAPEUTICS INC. (Exact name of Registrant as specified in its Charter)" This is the title of the company's annual report (Form 10-K) filed with the Securities and Exchange Commission (SEC).
Press release · 02/14 22:05
Aptevo Therapeutics files $100M mixed securities shelf
TipRanks · 02/14 21:15
More
About APVO
More
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Recently
Symbol
Price
%Change

Webull offers Aptevo Therapeutics Inc stock information, including NASDAQ: APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.